Trump Imposes Tariffs on Pharmaceuticals and Adjusts Metal Import Duties

These tariffs could reshape U.S. healthcare costs and manufacturing dynamics, impacting both consumers and industries.

• On April 2, 2026, President Trump signed proclamations imposing tariffs up to 100% on certain imported patented pharmaceuticals.
• Metal tariffs were adjusted, retaining 50% duties on raw materials while simplifying valuation for imported products.
• Exemptions apply for generics and negotiated deals, with effective dates staggered for different sectors.

• 53% of patented pharmaceuticals consumed in the U.S. are sourced from abroad, raising national security concerns.
• Previous tariffs under Section 232 were ruled unconstitutional, prompting a shift to sector-specific measures to incentivize domestic production.
• The U.S. Chamber of Commerce warns that these tariffs could increase healthcare costs, while some manufacturers support the changes for their protective benefits.

The recent proclamations signed by President Trump represent a strategic pivot in U.S. trade policy, particularly concerning national security and economic independence. The imposition of tariffs on patented pharmaceuticals and active pharmaceutical ingredients (APIs) stems from a Commerce Department investigation that revealed a heavy reliance on foreign sources—53% of patented drugs and 85% of APIs are imported. This dependence poses risks to supply chains, especially amid geopolitical tensions with countries like China.

The tariffs on pharmaceuticals are designed to encourage foreign producers to commit to onshoring production and reducing prices. The structure of these tariffs is tiered: a 20% interim tariff will escalate to 100% by 2030 for companies that do not comply with U.S. onshoring and pricing commitments. Notably, exemptions are granted to generics, orphan drugs, and specialty medications from allied nations, which could mitigate some immediate impacts on consumers.

In parallel, the adjustments to metal tariffs simplify the valuation process for imports. While maintaining a 50% duty on raw steel, aluminum, and copper, the new policy shifts the duty application to the full U.S. sales value rather than the previous complex calculations based on metal content. This change aims to streamline compliance for importers and reduce administrative burdens, although it still imposes significant costs on products with over 15% metal content.

The backdrop to these measures is the Supreme Court's ruling earlier in 2026, which invalidated broad reciprocal tariffs announced on "Liberation Day" in April 2025. This ruling necessitated a more targeted approach to tariffs, focusing on specific sectors rather than blanket measures. The adjustments reflect an ongoing effort to bolster domestic production capabilities while navigating the complexities of international trade relationships.

The economic implications are significant. The U.S. Trade Representative has indicated that these tariffs could generate an estimated $70 billion in additional revenue, which could be reinvested into domestic industries. However, the U.S. Chamber of Commerce has raised concerns about the potential for increased healthcare costs and supply chain disruptions, particularly in the pharmaceutical sector. As companies like Pfizer and Merck negotiate zero-tariff deals, the landscape of pharmaceutical pricing and availability is poised for transformation.

• Consumers: Higher prices for branded drugs and potential shortages of certain medications.
• Pharmaceutical companies: Pressure to comply with onshoring and pricing commitments to avoid tariffs.
• Metal importers: Adjustments in cost structures due to new valuation methods and duties.
• Healthcare providers: Increased costs may be passed on to patients, affecting access to medications.
• U.S. manufacturers: Opportunities for growth in domestic production, but potential volatility in raw material costs.

• Compliance rates: Monitor how quickly pharmaceutical companies adapt to onshoring requirements and pricing commitments.
• Market reactions: Watch for shifts in healthcare costs and availability of medications as tariffs take effect.
• Trade negotiations: Keep an eye on potential reciprocal trade agreements with the EU and other allies that could influence tariff structures.